| Drug ID: | Drug66 |
|---|---|
| Drug Name: | Ferric maltol |
| CID: | 169535 |
| DrugBank ID: | DB15598 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT05456932, , NCT01340872 |
| Molecular Formula: | C18H15FeO9 |
| Molecular Weight: | 431.2 g/mol |
| Isomeric SMILES: | CC1=C(C(=O)C=CO1)[O-].CC1=C(C(=O)C=CO1)[O-].CC1=C(C(=O)C=CO1)[O-].[Fe+3] |
| Synonyms: | Ferric maltol; Iron (III) maltol; st10; iron maltol; MA10QYF1Z0; UNII-MA10QYF1Z0; ST10-021; ST-10; Iron, tris(3-hydroxy-2-methyl-4H-pyran-4-onato-O3,O4)-; Feraccru |
| Phase 0: | 0 |
| Phase 1: | 3 |
| Phase 2: | 0 |
| Phase 3: | 7 |
| Phase 4: | 3 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT05456932 | Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease | PHASE4 | UNKNOWN | Leiden University Medical Center | Inflammatory Bowel Diseases|Iron-deficiency|Iron … | DRUG: Intravenous iron|DRUG: Ferric maltol|DRUG: … | Details |
| NCT02680756 | Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD | PHASE3 | COMPLETED | Shield Therapeutics | Anemia, Iron-Deficiency|Inflammatory Bowel Diseas… | DRUG: Ferric Maltol|DRUG: Ferric Carboxy Maltose | Details |
| EUCTR2022-000894-16-NL | Predicting Response to Iron Supplementation in Patients with active Inflammatory Bowel Disease - PRIme | PHASE4 | Not Recruiting | Leiden University Medical Center | Inflammatory Bowel Disease MedDRA version: 20.0 L… | Trade Name: FeraccruPharmaceutical Form: Capsule,… | Details |
| EUCTR2015-002496-26-DE | A phase 3b, randomized, controlled, multicentre study with oral ferric maltol (Feraccru) or intravenous iron (ferric carboxymaltose; FCM), for the treatment of iron deficiency anaemia in subjects with inflammatory bowel disease - ST10 versus IV iron for I | PHASE3 | Not Recruiting | Shield TX (UK) Ltd. | Iron deficiency anaemia with inflammatory bowel d… | Trade Name: Feraccru Product Name:… | Details |
| NCT04008901 | The Efficacy and Safety of BST104 (Lonicera Flos Extract) in Mild to Moderate Functional Dyspepsia Subjects | PHASE3 | COMPLETED | Seoul National University Bundang Hospital | Functional Dyspepsia|Irritable Bowel Syndrome | DRUG: BST-104 (Lonicera Flos Extract)|DRUG: Place… | Details |
| NCT01352221 | Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2) | PHASE3 | COMPLETED | Shield Therapeutics | Iron Deficiency Anaemia|Inflammatory Bowel Diseas… | DRUG: ST10|DRUG: Placebo oral capsule | Details |
| NCT01340872 | Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1) | PHASE3 | COMPLETED | Shield Therapeutics | Iron Deficiency Anaemia|Inflammatory Bowel Diseas… | DRUG: ST10-021|DRUG: Placebo Comparator | Details |
| NCT05581420 | Oral Versus Intravenous Iron in IBD Patients With Anti-inflammatory Therapy. | NA | UNKNOWN | Leiden University Medical Center | Inflammatory Bowel Diseases | DRUG: Ferrous fumarate|DRUG: MonoFer | Details |
| NCT07141238 | Microplastic Analysis in Pediatric Inflammatory Bowel Disease | NULL | RECRUITING | Medical University of Gdansk | Crohn Disease|Pediatric Inflammatory Bowel Diseas… | OTHER: Environmental microplastic exposure | Details |
| NCT05225545 | Sucrosomial Iron vs. Oral Iron Sulfate for the Treatment of Iron Deficiency Anemia in Patients With Ulcerative Colitis | PHASE3 | UNKNOWN | American University of Beirut Medical Center | Anemia, Iron Deficiency|Ulcerative Colitis | DRUG: Sucrosomial Iron|DRUG: Oral Iron | Details |
| NCT05176795 | Host-microbiota-environment Interactions | NULL | TERMINATED | University Hospital, Clermont-Ferrand | Juvenile Idiopathic Arthritis|Diabetes type1|Infl… | OTHER: Stool sample | Details |
| NCT04960826 | Study of an Environmental Risk Factor in Crohn's Disease | NULL | RECRUITING | University Hospital, Lille | Inflammatory Bowel Diseases | None | Details |
| NCT04587141 | Clinical Burden of Anemia in Inflammatory Bowel Disease: Therapeutic Trial | PHASE3 | UNKNOWN | Fondazione IRCCS Policlinico San Matteo di Pavia | Iron Deficiency Anemia|Inflammatory Bowel Diseases | DRUG: Sucrosomial iron|DRUG: Ferric Gluconate|DRU… | Details |
| NCT04565821 | Feasibility Study to Assess a Trans-nasal Intestinal Potential Difference Probe | NA | ACTIVE_NOT_RECRUITING | Massachusetts General Hospital | Inflammatory Disease|Permeability; Increased|Croh… | DEVICE: IPD Probe via TNIT | Details |
| NCT04318405 | Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE). | NULL | COMPLETED | Pierre Fabre Pharma AG | Iron-Deficiency Anemia|Iron-Deficiency | DRUG: Iron isomaltoside 1000 | Details |
| NCT07380022 | Acceptability, Adherence, and Impact on the Bioavailability of Iron and Zinc of the Dietary Supplements Goodphyte IB Defense and Goodphyte Immunity in Adults With Chronic Diseases. | NA | RECRUITING | University of Thessaly | IBD|Hypertension (HTN)|Multiple Sclerosis|Anemia|… | DIETARY_SUPPLEMENT: Dietary supplement interventi… | Details |
| NCT04123990 | Study of the Prevalence of Iron Deficiency in Patients With Chronic Inflammatory Bowel Disease | NA | UNKNOWN | VIFORFRANCE | Intestinal Disease | DIAGNOSTIC_TEST: Iron status testing | Details |
| NCT03872622 | Intestinal Response Patterns to Microbial Signals | NA | COMPLETED | Sheba Medical Center | CD - Crohn's Disease | OTHER: Blood tests, intestinal biopsies, stool sa… | Details |
| NCT03466983 | A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease | PHASE4 | COMPLETED | Pharmacosmos A/S | IBD | DRUG: Iron Isomaltoside|DRUG: Ferric Carboxymalto… | Details |
| NCT03457571 | Clinical Observational Study: IBD Patients With Restless-legs-syndrome and Iron Deficiency Syndrome | NULL | COMPLETED | Charite University, Berlin, Germany | Inflammatory Bowel Diseases|Restless Legs Syndrom… | None | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymalt…
PMID: 33988236
Year: 2022
Relationship Type:
Treatment
Score: 9.5
BACKGROUND: Iron-deficiency anemia is common in inflammatory bowel disease, requiring oral or intravenous iron replacement therapy. Treatment with st…
Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory…
PMID: 27237709
Year: 2016
Relationship Type:
Treatment
Score: 9.3
BACKGROUND: Ferric maltol was effective and well-tolerated in iron deficiency anaemia patients with inflammatory bowel disease during a 12-week place…
Ferric maltol is effective in correcting iron deficiency anemia in patients wit…
PMID: 25545376
Year: 2015
Relationship Type:
Treatment
Score: 9.3
BACKGROUND: Iron deficiency anemia (IDA) is frequently seen in inflammatory bowel disease. Traditionally, oral iron supplementation is linked to exte…
Ferric maltol (ST10): a novel oral iron supplement for the treatment of iron de…
PMID: 26595432
Year: 2015
Relationship Type:
Treatment
Score: 8.3
Dysregulation of the key genetic, immunologic, and microbiome compounds of the gut-liver axis is the basis for inflammatory bowel disease (IBD) and …
Oral Ferric Maltol Does Not Adversely Affect the Intestinal Microbiome of Patie…
PMID: 34209042
Year: 2021
Relationship Type:
Treatment
Score: 7.5
BACKGROUND AND AIMS: Altering dietary ferrous sulphate (FS) consumption exacerbates a murine model of colitis and alters the intestinal microbiome. W…
Iron Replacement Therapy with Oral Ferric Maltol: Review of the Evidence and Ex…
PMID: 34640466
Year: 2021
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Clostridioides difficile infection (CDI) and inflammatory bowel disease (IBD) are global gastroenterological diseases that cause conside…
Corrigendum to: Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Fe…
PMID: 34612489
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Ferric maltol Real-world Effectiveness Study in Hospital practice (FRESH): clin…
PMID: 33622683
Year: 2021
Relationship Type:
Treatment
Score: 6.5
Comment in Inflamm Bowel Dis. 2022 May 4;28(5):e59-e60. Inflamm Bowel Dis. 2022 May 4;28(5):e61. BACKGROUND: Infliximab and adalimumab conce…
Ferric Maltol: A New Oral Iron Formulation for the Treatment of Iron Deficiency…
PMID: 32633548
Year: 2021
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIM: Inflammatory bowel disease (IBD) patients are at risk for recurrent Clostridium difficile infection (RCDI). We aimed to evaluate…
Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in…
PMID: 27101422
Year: 2017
Relationship Type:
Treatment
Score: 6.3
AIM: To investigate the therapeutic effect of hydrogen-rich water (HRW) on inflammatory bowel disease (IBD) and to explore the potential mechanisms …
Predicting response to iron supplementation in patients with active inflammator…
PMID: 38296290
Year: 2024
Relationship Type:
Treatment
Score: 5.5
INTRODUCTION: Iron deficiency anaemia (IDA) is the most common systemic manifestation of inflammatory bowel disease (IBD) that has detrimental effect…
Nano-formulations in treatment of iron deficiency anaemia: An overview
PMID: 36513444
Year: 2022
Relationship Type:
Treatment
Score: 5.5
BACKGROUND: Iron deficiency anaemia (IDA) is a significant challenge to global health. The absorption and bioavailability depend on the delivery vehi…
One-Step Preparation of an AgNP-nHA@RGO Three-Dimensional Porous Scaffold and I…
PMID: 32764934
Year: 2020
Relationship Type:
Treatment
Score: 5.5
OBJECTIVE: To review the pharmacology, efficacy, and safety of ferric maltol (FM), an oral iron formulation, for iron deficiency anemia (IDA). DATA …